RECRUITING

Protocol for Genomically Profiling, Collecting, Archiving and Distributing Blood and Bone Marrow Specimens from Children and Young Adults with Hematologic Malignancy

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This research study is a genomic profiling and repository study for children and young adults who have leukemia, myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS). Genes are the part of cells that contain the instructions which tell cells how to make the right proteins to grow and work. Genes are composed of DNA letters that spell out these instructions. Genomic profiling helps investigators understand why the disease develops and the instructions that led to its development. Understanding the genetic factors of the disease can also help investigator understand why the disease of some people can respond to certain therapies differently than others. The genomic profiling will be performed using bone marrow and blood samples that either have already been obtained during a previous clinical procedure or will be obtained at the time of a scheduled clinical procedure. Studying the genetic information in the cells of these samples will provide information about the origin, progression, and treatment of leukemia and myeloproliferative syndromes and myelodysplastic syndrome. Storing the bone marrow and blood samples will allow for additional research and genomic assessments to be performed in the future.

Official Title

Protocol for Genomically Profiling, Collecting, Archiving and Distributing Blood and Bone Marrow Specimens from Children and Young Adults with Hematologic Malignancy

Quick Facts

Study Start:2021-06-11
Study Completion:2033-06
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04968834

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified to 30 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age: birth to \< 30 years of age
  2. * Diagnosis:
  3. * Pathology Criteria:
  4. * Specimen Criteria:
  5. * Sufficient sample available for genomic profiling OR bone marrow aspirate/blood draw planned for clinical care which is anticipated to allow collection of minimum specimen for testing (See Section 6.1 for description of specimen requirements)
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Yana Pikman, MD
CONTACT
(617) 632-4754
yana_pikman@dfci.harvard.edu

Principal Investigator

Yana Pikman, MD
PRINCIPAL_INVESTIGATOR
Dana-Farber Cancer Institute

Study Locations (Sites)

Connecticut Children's Medical Center
Hartford, Connecticut, 06106
United States
Maine Medical Center
Portland, Maine, 04102
United States
Boston Children's Hospital
Boston, Massachusetts, 02115
United States
Dana Farber Cancer Institute
Boston, Massachusetts, 02215
United States
Dartmouth-Hitchcock
Lebanon, New Hampshire, 03756
United States
Albany Medical Center
Albany, New York, 12208
United States
Lifespan Cancer Institute
Providence, Rhode Island, 02903
United States
University of Vermont Medical Center
Burlington, Vermont, 05401
United States

Collaborators and Investigators

Sponsor: Dana-Farber Cancer Institute

  • Yana Pikman, MD, PRINCIPAL_INVESTIGATOR, Dana-Farber Cancer Institute

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-06-11
Study Completion Date2033-06

Study Record Updates

Study Start Date2021-06-11
Study Completion Date2033-06

Terms related to this study

Keywords Provided by Researchers

  • Leukemia
  • Myelodysplastic Syndromes
  • Myeloproliferative syndrome (MPS)

Additional Relevant MeSH Terms

  • Leukemia
  • Myelodysplastic Syndromes
  • Myeloproliferative Syndrome